vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
CROSS COUNTRY HEALTHCARE INC is the larger business by last-quarter revenue ($236.8M vs $207.8M, roughly 1.1× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -35.0%, a 92.4% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $16.1M).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
CCRN vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $207.8M |
| Net Profit | $-82.9M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | -30.2% | 52.2% |
| Net Margin | -35.0% | 57.4% |
| Revenue YoY | -23.6% | — |
| Net Profit YoY | -2109.7% | 330.1% |
| EPS (diluted) | $-2.56 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | — | ||
| Q3 25 | $250.1M | $207.8M | ||
| Q2 25 | $274.1M | — | ||
| Q1 25 | $293.4M | — | ||
| Q4 24 | $309.9M | — | ||
| Q3 24 | $315.1M | $0 | ||
| Q2 24 | $339.8M | $0 | ||
| Q1 24 | $379.2M | $0 |
| Q4 25 | $-82.9M | — | ||
| Q3 25 | $-4.8M | $119.2M | ||
| Q2 25 | $-6.7M | — | ||
| Q1 25 | $-490.0K | — | ||
| Q4 24 | $-3.8M | — | ||
| Q3 24 | $2.6M | $-51.8M | ||
| Q2 24 | $-16.1M | $-52.8M | ||
| Q1 24 | $2.7M | $-39.6M |
| Q4 25 | — | — | ||
| Q3 25 | 20.4% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 20.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 20.4% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | -30.2% | — | ||
| Q3 25 | -2.4% | 52.2% | ||
| Q2 25 | -2.1% | — | ||
| Q1 25 | -0.3% | — | ||
| Q4 24 | -1.1% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | -5.7% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -35.0% | — | ||
| Q3 25 | -1.9% | 57.4% | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | -0.2% | — | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | $-2.56 | — | ||
| Q3 25 | $-0.15 | $1.33 | ||
| Q2 25 | $-0.20 | — | ||
| Q1 25 | $-0.02 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $0.08 | $-0.60 | ||
| Q2 24 | $-0.47 | $-0.68 | ||
| Q1 24 | $0.08 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $322.8M | $1.1B |
| Total Assets | $449.0M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | — | ||
| Q3 25 | $99.1M | $786.9M | ||
| Q2 25 | $81.2M | — | ||
| Q1 25 | $80.7M | — | ||
| Q4 24 | $81.6M | — | ||
| Q3 24 | $64.0M | $920.0M | ||
| Q2 24 | $69.6M | $701.7M | ||
| Q1 24 | $5.2M | $698.8M |
| Q4 25 | $322.8M | — | ||
| Q3 25 | $408.1M | $1.1B | ||
| Q2 25 | $412.2M | — | ||
| Q1 25 | $418.2M | — | ||
| Q4 24 | $419.0M | — | ||
| Q3 24 | $424.7M | $1.2B | ||
| Q2 24 | $433.3M | $931.7M | ||
| Q1 24 | $462.4M | $935.3M |
| Q4 25 | $449.0M | — | ||
| Q3 25 | $538.2M | $1.2B | ||
| Q2 25 | $553.8M | — | ||
| Q1 25 | $576.2M | — | ||
| Q4 24 | $589.3M | — | ||
| Q3 24 | $597.4M | $1.2B | ||
| Q2 24 | $602.9M | $973.7M | ||
| Q1 24 | $648.4M | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $142.2M |
| Free Cash FlowOCF − Capex | $16.1M | $142.2M |
| FCF MarginFCF / Revenue | 6.8% | 68.4% |
| Capex IntensityCapex / Revenue | 0.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | — | ||
| Q3 25 | $20.1M | $142.2M | ||
| Q2 25 | $4.2M | — | ||
| Q1 25 | $5.7M | — | ||
| Q4 24 | $24.2M | — | ||
| Q3 24 | $7.5M | $-49.2M | ||
| Q2 24 | $82.4M | $-32.9M | ||
| Q1 24 | $6.0M | $-43.8M |
| Q4 25 | $16.1M | — | ||
| Q3 25 | $17.9M | $142.2M | ||
| Q2 25 | $2.3M | — | ||
| Q1 25 | $3.8M | — | ||
| Q4 24 | $21.7M | — | ||
| Q3 24 | $6.3M | $-49.7M | ||
| Q2 24 | $79.6M | $-33.9M | ||
| Q1 24 | $3.8M | $-45.1M |
| Q4 25 | 6.8% | — | ||
| Q3 25 | 7.2% | 68.4% | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 23.4% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.9% | 0.0% | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
IDYA
Segment breakdown not available.
